Experience with Relatox® in the combination therapy of arm and hand spasticity after stroke

Objective: to evaluate the safety, efficacy, and tolerability of the botulinum toxin A Relatox® in arm and hand spasticity after ischemic stroke in routine clinical practice.
Patients and methods. The instigation enrolled 7 patients after ischemic stroke (7 years ago) with the signs of upper limb spasticity. All the patients received combination treatment that involved daily kinesiotherapy sessions and electrical stimulation of the paralyzed limbs. Relatox® was once injected into the forearm muscles of the paralyzed arm 6 months or later after stroke. Muscles were chosen according to clinical and electromyographic findings. The patients' status was assessed before, 2 weeks and 3 months after injection.
There were changes in muscle tone, motor abilities of the hand, in the degree of self-service, the presence of subjective sensations, and the degree of local and systemic reactions. The efficiency of therapy was evaluated clinically (Ashworth scale, Frenchay test, Barthel index) and on the basis of an analysis of video monitoring a patient's status and of the consideration of care-givers' views.
Before included in the study, all the patients were treated with different types of botulinum neurotoxin type A made by other manufacturers.
Results. The clinical efficiency of local intramuscular injection of the botulinum toxin type Relatox® in combination with kinesiotherapy and electrical stimulation after 14 days and 3 months after injection was noted in all cases.
The good tolerability, efficacy, and long-term of action of relatox, which were comparable to those of other botulinum neurotoxin type A products, were noted during a 3-month follow-up. Neither side effects no adverse events were identified.
Conclusion. Accumulation of data on the doses and effects of drugs for the local therapy of post-stroke spasticity, which have been obtained by different clinical centers, and the possibility of choosing a medication will be able to improve treatment in such patients.

1. Суслина ЗС, Танашян ММ, Ионова ВГ. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. Москва: Медкнига; 2005. 248 с. [Suslina ZS, Tanashyan MM, Ionova VG. Ishemicheskii insul't: krov', sosudistaya stenka, antitromboticheskaya terapiya [Ischemic stroke: blood, vascular wall, antithrombotic therapy]. Moscow: Medkniga; 2005. 248 p.]

2. Стаховская ЛВ, Клочихина ОА, Богатырева МД, Коваленко ВВ. Эпидемиология инсульта в России по результатам территориально-популяционного регистра (2009–2010). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(5):4-10. [Stakhovskaya LV, Klochikhina OA, Bogatyreva MD, Kovalenko VV. Epidemiology of stroke in Russia according to the results of the territorial-population registry (2009–2010). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;113(5):4-10. (In Russ.)].

3. Кадыков АС, Черникова ЛА, Шахпаронова НВ. Реабилитация неврологических больных. Москва: МЕДпресс-информ; 2009. 560 с. [Kadykov AS, Chernikova LA, Shakhparonova NV. Reabilitatsiya nevrologicheskikh bol'nykh [Rehabilitation of neurological patients]. Moscow: MEDpress-inform; 2009. 560 p.]

4. Штульман ДР, Левин ОС. Неврология: справочник практикующего врача. 5-е изд. Москва: МЕДпресс-информ; 2007. 960 с. [Shtul'man DR, Levin OS. Nevrologiya: spravochnik praktikuyushchego vracha [Neurology: a handbook of the medical practitioner]. 5th ed. Moscow: MEDpress-inform; 2007. 960 p.]

5. Завалишин ИА, Стойда НИ, Шитикова ИЕ. Клиническая характеристика синдрома верхнего мотонейрона. В кн.: Завалишин ИА, редактор. Синдром верхнего мотонейрона. Самара: Самарское отделение Литфонда; 2005. С. 11-54. [Zavalishin IA, Stoida NI, Shitikova IE. Clinical characteristics of the syndrome of upper motor neuron. In: Zavalishin IA, editor. Sindrom verkhnego motoneirona [Syndrome of upper motor neuron]. Samara: Samarskoe otdelenie Litfonda; 2005. P. 11-54.]

6. Артеменко АР, Куренков АЛ, Беломестова КВ. К вопросу об отсутствии взаимозаменяемости лекарственных препаратов ботулинического токсина типа А. Медицинский совет. 2015;(5):112-23. [Artemenko AR, Kurenkov AL, Belomestova KV. On the absence of interchangeability of botulinum toxin type A drugs. Meditsinskii sovet. 2015;(5):112-23. (In Russ.)].

7. Хатькова СЕ, Костенко ЕВ, Похабов ДВ и др. Оценка безопасности и эффективности российского препарата ботулотоксина А Релатокс® в сравнении с Ботоксом® при спастичности руки после ишемического инсульта (мультицентровое рандомизированное исследование). Неврология, нейропсихиатрия, психосоматика. 2017;9(1):71-7. [Khat'kova SE, Kostenko EV, Pokhabov DV, et al. Evaluation of the safety and efficacy of the Russian botulinum toxin-A relatox versus botox in treating arm and hand spasticity after ischemic stroke: A multicenter randomized trial. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(1):71-7. (In Russ.)]. doi: 10.14412/2074-2711-2017-1-71-77